RLAY

Relay TherapeuticsC

Nasdaq / Pharmaceuticals, Biotechnology & Life Sciences

At close

2026-06-02

View Chart

AI scenario view

RankAlpha Sentiment CodexPost-earnings T+3

B+

Bull case

25%

Probability

Target price

$17.00

+8.3% vs current

Most likely

Base case

50%

Probability

Target price

$13.50

-14.0% vs current

B-

Bear case

25%

Probability

Target price

$8.50

-45.9% vs current

AI sentiment snapshot

Latest data as of 2026-05-08

AI commentary

This is still a monitoring-style T+3 earnings memo, not a conviction upgrade. Primary-source support is solid after the May 5 8-K, 10-Q, and company earnings release, but external revision evidence remains thin. The stock’s anchor moved from $13.03 on 2026-04-28 in the prior baseline to $12.51 on 2026-05-07, which suggests mildly negative post-print digestion even though cash runway improved and milestones stayed on track. With no trustworthy checked evidence of a meaningful post-earnings analyst rerating, the tone stays cautious rather than decisively bullish.

RankAlpha Sentiment Codex - 2026-05-08

Open post-earnings memo

Evidence flagged

No evidence quality warning is currently attached to this memo.

Impact

standard

Confidence

AI events

2026-05-19catalystQ1 update extended cash runway and kept the zovegalisib calendar activeHigh impact

Relay’s May 5 earnings release said cash, cash equivalents and investments ended Q1 2026 at approximately $642 million and should fund operations into 2029, while also reiterating a May 19 vascular-anomalies data event and ongoing breast-cancer execution. That reduces near-term financing pressure but does not remove clinical-event dependence [#8-K-2026-05-05] [#PR-2026-05-05].

2026-05-20eventInitial vascular anomalies data remain the nearest clean clinical readoutHigh impact

Relay previously guided to initial zovegalisib clinical results in PIK3CA-driven vascular anomalies at ISSVA World Congress 2026 on May 20, 2026, and the May 5 Q1 update again flagged a May 19 conference call during ISSVA. This is the next discrete proof-of-concept checkpoint beyond breast-cancer narrative updates [#PR-2026-04-02] [#PR-2026-05-05].

2027-03-31catalystBreast-cancer program execution still hinges on Phase 3 and frontline triplet follow-throughHigh impact

Relay’s core value driver remains zovegalisib. The company said ReDiscover-2 is ongoing, FDA Breakthrough Therapy designation was granted in February 2026 for the fulvestrant doublet setting, and the zovegalisib plus atirmociclib triplet is the go-forward frontline regimen with a Phase 3 study expected to start in early 2027, subject to regulatory feedback. That is strategically positive, but the setup is still clinical-execution heavy rather than commercially de-risked [#10-Q-2026-05-05] [#PR-2026-05-05] [#8-K-2026-04-27].

View full catalyst timeline

Recommendation

N/A

No formal recommendation provided.

Open AI Memo

As of 2026-05-08 • Updated nightlySource: Internal modelMethodology